Ensure equitable access to reliable diagnosis around the world

Despite the ongoing challenges of the COVID-19 pandemic, FIND capitalized on its recently launched strategy and achieved its 2021 goals, delivering an average of 81% of programmatic performance objectives (versus 80% target). Outside COVID, four products in FIND’s product development portfolio received regulatory clearance; evidence was generated to support six World Health Organization (WHO) recommendations and policy documents; and 36 clinical studies were conducted, 28 of which relied on newly developed approaches to remote work and remote training. Notably, in 2021, FIND was especially focused on its role in supporting global access to COVID-19 tests and genomic sequencing, through its role in the Access to COVID-19 Tools Accelerator Diagnostics Pillar (ACT-A Dx). In part, this meant engaging substantially with multiple global agencies, and absorbing a large injection of COVID-19 work into ongoing work across FIND’s disease portfolio, including in pandemics threats.